Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting

NCT ID: NCT05916105

Last Updated: 2023-06-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 151 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-09-01
• Study Completion Date: 2022-03-01

Brief Summary

Background: Ciprofloxacin is a fluoroquinolone that is commonly used to treat a variety of diseases. Ciprofloxacin resistance is rising, resulting in suboptimal patient care. The goal of this study was to evaluate ciprofloxacin use in the community in terms of acceptable prescription, dose, frequency, and duration of use.

Methods: A cross-sectional research was done in Egyptian community pharmacies by community pharmacists. Patients who were administered oral ciprofloxacin during the research period were included.

Detailed Description

From September 2021 to February 2022, a cross-sectional, research was undertaken to evaluate ciprofloxacin usage. The investigation was carried out by community pharmacists in seven Egyptian community pharmacies.

Data Collection: data gathered from pharmacy patients' records on a data collection form that included the factors indicated. The General Symptoms Questionnaire, physical examination, and blood testing were used to identify adverse occurrences.

Study variables:

• age, gender, pregnancy/lactation
• Department/indication
• Dose, Frequency, Duration, Adverse events, Drug interactions.

Data was categorized and analyzed using appropriate software.

Conditions

Ciprofloxacin Adverse Reaction

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: RETROSPECTIVE

Study Groups

Ciprofloxacin

151 record of Ciprofloxacin

Ciprofloxacin Tablets

Intervention Type: DRUG

Ciprofloxacin antibiotic

Interventions

Ciprofloxacin Tablets

Ciprofloxacin antibiotic

Intervention Type: DRUG

Other Intervention Names

Ciprofloxacin

Eligibility Criteria

Inclusion Criteria

• All ciprofloxacin included prescription during the study period.

Exclusion Criteria

• un included ciprofloxacin prescription.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Damanhour University

OTHER

Sponsor Role: lead

Responsible Party

Rehab Werida

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Rehab H Werida, Ass. Prof.

Role: STUDY_DIRECTOR

Damanhour University

Locations

Rehab Hussein Werida

Damanhūr, Elbehairah, Egypt

Countries

Egypt

References

Goldman MP. Ciprofloxacin drug utilization review and prospective drug use evaluation. DICP. 1990 Jan;24(1):82-6. doi: 10.1177/106002809002400115.

Reference Type: BACKGROUND

PMID: 2301191 (View on PubMed)

Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010.

Reference Type: BACKGROUND

PMID: 8736621 (View on PubMed)

Other Identifiers

Ciprofloxacin Utilization

Identifier Type: -

Identifier Source: org_study_id